We therefore examined the expression of validated ERRγ target genes in publicly available ER+ breast cancer datasets as a proxy for receptor activity rather than expression, which we propose is similarly a more relevant measure of in vivo ERRγ function in endocrine therapy response and resistance. The gene discussed is ESRRG; the disease is breast carcinoma.